Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $72.5 million.

  • UNITED THERAPEUTICS's Depreciation & Amortization (CF) rose 14.66% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.5 million, marking a year-over-year increase of 24.06%. This contributed to the annual value of $72.5 million for FY2024, which is 36.28% up from last year.
  • As of FY2024, UNITED THERAPEUTICS's Depreciation & Amortization (CF) stood at $72.5 million, which was up 36.28% from $53.2 million recorded in FY2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Depreciation & Amortization (CF) peaked at $72.5 million during FY2024, and registered a low of $49.9 million during FY2020.
  • For the 3-year period, UNITED THERAPEUTICS's Depreciation & Amortization (CF) averaged around $59.0 million, with its median value being $53.2 million (2023).
  • Data for UNITED THERAPEUTICS's Depreciation & Amortization (CF) shows a peak YoY surged of 36.28% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Depreciation & Amortization (CF) stood at $49.9 million in 2020, then remained steady at $49.9 million in 2021, then rose by 2.81% to $51.3 million in 2022, then climbed by 3.70% to $53.2 million in 2023, then skyrocketed by 36.28% to $72.5 million in 2024.